Can AI and Blood Tests Detect Cancer Earlier?

Blood tests are beginning to change how researchers think about cancer detection and monitoring. Instead of waiting for a tumor to become visible on a scan or cause symptoms, some emerging tests search the bloodstream for fragments of DNA associated with cancer.

Artificial intelligence and machine-learning systems can help analyze these complex molecular patterns. The technology is promising, especially for cancers that lack routine screening options, but it is not a shortcut to a diagnosis. A cancer signal in the blood still requires careful medical evaluation, and a negative test cannot guarantee that cancer is absent.

What are multi-cancer early detection blood tests?

Multi-cancer detection tests are being studied as a way to screen for several cancers with one blood draw. They measure biological signals, including DNA fragments released into the bloodstream, that may indicate cancer is present.

The National Cancer Institute explains that these tests make a prediction about the possible presence of cancer rather than establishing a diagnosis. The NCI overview of multi-cancer detection tests also notes that additional testing is required after an abnormal result.

How does Galleri use DNA analysis and machine learning?

Galleri, developed by GRAIL, looks for patterns in cell-free DNA circulating in the blood. The test uses a machine-learning algorithm to evaluate whether DNA fragments appear more consistent with healthy cells or cancer cells and to predict the most likely location of origin when a cancer signal is detected.

GRAIL states that Galleri screens for signals associated with more than 50 types of cancer. The official Galleri test description explains the role of DNA analysis and machine learning in that process.

This is where artificial intelligence may add meaningful value. A blood sample can contain an enormous amount of molecular information. Machine learning can help identify patterns that would be difficult to evaluate manually, but the algorithm does not independently diagnose cancer.

Can Galleri diagnose cancer from a blood sample?

No. A cancer-signal-detected result is not a confirmed diagnosis. Imaging, additional laboratory testing, endoscopy, or a biopsy may be necessary to determine whether cancer is actually present and where it is located.

MD Anderson Cancer Center advises that multi-cancer detection tests can produce false positive and false negative results, remain under study, and do not replace established screening. Its medical overview of multi-cancer detection testing emphasizes both the potential and the unresolved questions.

How is Signatera different from a general cancer screening test?

Signatera, developed by Natera, serves a different purpose. It is a personalized, tumor-informed circulating tumor DNA test. A sample from a patient’s known tumor is used to identify a distinctive set of mutations. Later blood draws can then be checked for DNA that matches that tumor profile.

This approach is used for molecular residual disease assessment, treatment-response monitoring, and recurrence monitoring in selected clinical settings. The official Signatera overview describes how the assay is customized to each patient’s tumor.

Galleri asks whether a blood sample contains a signal that may point to one of many cancers. Signatera asks whether DNA connected to a cancer already identified in a particular patient can still be detected after treatment or during follow-up.

What did the FDA authorize for Signatera CDx in 2026?

On May 15, 2026, the Food and Drug Administration approved Signatera CDx for a specific companion-diagnostic use involving patients with muscle-invasive bladder cancer after cystectomy. The test identifies circulating tumor DNA molecular residual disease status to help determine eligibility for an approved adjuvant treatment.

The FDA premarket approval record for Signatera CDx is limited to that stated indication. It should not be interpreted as blanket FDA approval for every Signatera use across every cancer type.

Can cancer blood tests replace mammograms, colonoscopies, or biopsies?

No. Multi-cancer blood tests do not replace recommended mammograms, colonoscopies, cervical-cancer screening, lung-cancer screening, or other established methods. They also do not replace diagnostic imaging or biopsy when cancer is suspected.

Traditional screening methods have evidence, eligibility guidelines, and performance characteristics developed for specific cancers. New blood tests may eventually complement those tools, but patients should not stop recommended screening because of a blood-test result.

What questions remain before these tests become routine cancer care?

The most important unanswered question is whether using these tests across broad populations will reduce deaths from cancer without causing excessive false alarms, unnecessary procedures, anxiety, or avoidable costs.

Researchers must also determine which patients benefit most, how often testing should occur, how results should guide follow-up care, and whether insurers will cover appropriate use. Artificial intelligence can improve pattern recognition, but clinical evidence must determine whether that technological promise produces better outcomes for patients.

The direction of cancer care is becoming clearer. Blood-based detection, personalized molecular monitoring, and advanced computational analysis are likely to play a larger role. The responsible path forward is to combine innovation with rigorous evidence, transparent limitations, and continued medical oversight.

Medical disclaimer: This article is for informational and educational purposes only. It is not medical advice and should not be used to diagnose cancer, select a test, or change a screening or treatment plan. Patients should discuss cancer screening and monitoring with a qualified healthcare professional.

Watch the full episode: Can AI and Blood Tests Detect Cancer Earlier?

© Copyright 2026 Claremont Management Group, Inc. All Rights Reserved. No copyright asserted over US Government material or the copyrighted material of others.